Clinical trials: Prophylaxis of Acute Mountain Sickness, active

Acute Mountain Sickness

Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness

• Not yet recruiting
• Age: 18 to 60 years
• Phase 4
• Injection or infusion

Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep.

Trial name

NCT07653516

Testing

Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

Where

Switzerland

Volunteers

30 people, healthy volunteers welcome

Sponsor

Insel Gruppe AG, University Hospital Bern